American Tungsten & Antimony Ltd
ATAYYDrugs in Pipeline
5
Phase 3 Programs
3
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Injectafer
Restless Legs Syndrome (RLS)
Ferric Carboxymaltose
Anemia
Ferrous Sulfate tablets
Anemia
Taxoprexin
Metastatic Melanoma
Ferric Carboxymaltose (FCM)
Restless Legs
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Injectafer | Phase 3 | Restless Legs Syndrome (RLS) | - | - |
Ferric Carboxymaltose | Phase 3 | Anemia | - | - |
Ferrous Sulfate tablets | Phase 3 | Anemia | - | - |
Taxoprexin | Phase 2 | Metastatic Melanoma | - | - |
Ferric Carboxymaltose (FCM) | Phase 2 | Restless Legs | - | - |
Frequently asked questions
What is in American Tungsten & Antimony Ltd's drug pipeline?→
CatalystAlert tracks 5 drug candidates in American Tungsten & Antimony Ltd's (ATAYY) pipeline across Phase 3, Phase 2. Its lead program is Injectafer (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is American Tungsten & Antimony Ltd's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for American Tungsten & Antimony Ltd (ATAYY) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ATAYY biotech catalysts?→
Add ATAYY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow American Tungsten & Antimony Ltd's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.